William Fairey
Director/Board Member at MIRUM PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-04-29
William Fairey active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Director/Board Member | 2021-08-18 | - |
| Independent Dir/Board Member | 2021-08-18 | - | |
| ASCENDIS PHARMA A/S | Director/Board Member | 2022-08-31 | - |
| Independent Dir/Board Member | 2022-08-31 | - | |
| AILERON THERAPEUTICS, INC. | Director/Board Member | 2023-10-30 | - |
| Independent Dir/Board Member | 2023-10-30 | - | |
| KALVISTA PHARMACEUTICALS, INC. | Director/Board Member | 2024-04-17 | - |
| Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. | Director/Board Member | - | - |
Respira Therapeutics, Inc.
 Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM. | Chairman | 2021-12-31 | - |
Career history of William Fairey
Former positions of William Fairey
| Companies | Position | Start | End |
|---|---|---|---|
Lung Therapeutics, Inc.
 Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Director/Board Member | 2021-08-30 | 2023-10-30 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 2018-12-31 | 2020-10-31 |
| CHEMOCENTRYX, INC. | Chief Operating Officer | 2018-01-07 | 2019-01-17 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of William Fairey
| St. Mary's College of California | Masters Business Admin |
| University of Oregon | Undergraduate Degree |
Statistics
International
| United States | 11 |
| Denmark | 2 |
| Australia | 2 |
Operational
| Director/Board Member | 6 |
| Corporate Officer/Principal | 3 |
| Independent Dir/Board Member | 3 |
Sectoral
| Health Technology | 11 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| AILERON THERAPEUTICS, INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| MIRUM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Health Technology |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Health Technology |
Australia Asia Pacific Hotels Ltd.
 Australia Asia Pacific Hotels Ltd. Hotels/Resorts/Cruise linesConsumer Services Australia Asia Pacific Hotels Ltd. is an Australian private company located in Sydney. The firm operates hotels. | Consumer Services |
Respira Therapeutics, Inc.
Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM. | Health Technology |
| Actelion Pharmaceuticals Canada, Inc. | |
Actelion Pharmaceuticals Ltd.
 Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The company is based in Allschwil, Switzerland. | Health Technology |
| Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. |
- Stock Market
- Insiders
- William Fairey
- Experience
